Drug Profile
Research programme: antibody-based immunotherapy - GlaxoSmithKline/Purdue
Latest Information Update: 25 May 2007
Price :
$50
*
At a glance
- Originator Purdue Biopharma; Purdue Pharma
- Developer GlaxoSmithKline; Purdue Biopharma
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Dec 2002 This programme is still in active development
- 02 Oct 2000 Preclinical development for Cancer in USA (Unknown route)